Stocktwits on MSN

ImmunityBio says phase 2 bladder cancer trial has ‘statistical power’ – Anktiva-BCG advances toward filing

ImmunityBio (IBRX) said on Thursday that its QUILT-2.005 clinical trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG ...

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versu…

ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated, commercial-stage immunotherapy company, today announced that based ...

ImmunityBio lead bladder cancer drug trial clears power check

ImmunityBio Inc. IBRX shares are down during Thursday’s premarket session. Year to date, the stock has jumped over 300%. The ...
ascopubs.org

Statistical Power of Negative Randomized Controlled Trials Presented at American Society for Clinical Oncology Annual Meetings

We surveyed all two-arm phase III RCTs presented at ASCO annual meetings from 1995 to 2003 for which negative results were obtained. Post hoc calculations were performed using a power of 80% and an α ...